Collegium Pharmaceutical, Inc. (COLL)
NASDAQ: COLL · Real-Time Price · USD
30.00
+0.25 (0.84%)
Nov 20, 2024, 4:00 PM EST - Market closed
Collegium Pharmaceutical Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for COLL stock have an average target of 42, with a low estimate of 37 and a high estimate of 50. The average target predicts an increase of 40.00% from the current stock price of 30.00.
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 11, 2024.
Analyst Ratings
The average analyst rating for COLL stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Hold Reiterates $37 | Hold | Reiterates | $37 | +23.33% | Oct 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $47 → $50 | Strong Buy | Maintains | $47 → $50 | +66.67% | Sep 5, 2024 |
| Piper Sandler | Piper Sandler | Hold Reiterates $39 → $37 | Hold | Reiterates | $39 → $37 | +23.33% | Aug 9, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $40 → $42 | Strong Buy | Maintains | $40 → $42 | +40.00% | Aug 9, 2024 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Aug 9, 2024 |
Financial Forecast
Revenue This Year
640.58M
from 566.77M
Increased by 13.02%
Revenue Next Year
755.97M
from 640.58M
Increased by 18.01%
EPS This Year
6.28
from 1.29
Increased by 385.24%
EPS Next Year
6.88
from 6.28
Increased by 9.67%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 663.8M | 804.2M | 872.2M | ||
| Avg | 640.6M | 756.0M | 776.1M | ||
| Low | 611.6M | 704.7M | 699.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 17.1% | 25.5% | 15.4% | ||
| Avg | 13.0% | 18.0% | 2.7% | ||
| Low | 7.9% | 10.0% | -7.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 6.59 | 7.46 | 8.57 | |
| Avg | 6.28 | 6.88 | 7.30 | |
| Low | 5.80 | 6.05 | 6.29 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 409.9% | 18.8% | 24.5% | |
| Avg | 385.2% | 9.7% | 6.1% | |
| Low | 348.6% | -3.6% | -8.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.